In a report published Monday, Jefferies & Company terminated its coverage on Biosante Pharmaceuticals BPAX.
Jefferies noted, “Due to a reallocation of resources, we are dropping coverage of BioSante Pharmaceuticals (BPAX). Our last rating on BioSante was Hold with a $2 price target...Our $2 PT was based on a DCF taken out to 2026, discounted at 20%. Our most recent published risks included the potential for additional dilutive financings and pipeline setbacks.”
Biosante Pharmaceuticals closed on Friday at $1.30.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in